|
Recent Developments |
|
21-JAN-19
Pharmaceutical and biotechnology major Wockhardt has received approval from the United States Food & Drug Administration (US FDA) for an ANDA for lOOmg and 400mg tablets
07-AUG-17
Wockhardt has received approval from the United States Food & Drug Administration (USFDA) for an ANDA for 1gm, and 2gm injections of Oxacillin. The pharma major is expected to launch this product in the United States, soon. The product is being manufactured... More.. |
| Business Profile |
Future Plans |
|
| CEO Talk | | Wockhardt Ltd is exploring possibilities of co-licensing WCK-771 and WCK-919. The company intends to focus essentially on the anti-infective therapeutic segment as it accounts for 12 per cent of the total pharma market and is the third largest therapeutic segment. Habil Khorakiwala |
|
|
One To One
|
|
Recent news
|
|
|
| Period ending (months) | 31-Dec-2017(9) | 31-Mar-2017 (12) | 31-Mar-2016(12) | | Net sales | 15639.50 | 22975.20 | 17135.70 | | Other Income | 462.90 | 2483.10 | 317.20 | | Total Income | 16102.40 | 25458.30 | 17452.90 | | Cost of goods sold | 17239.20 | 24270.50 | 15882.30 | | OPBDIT | -1136.80 | 1187.80 | 1570.60 | | PAT | -1037.80 | 1371.20 | 260.70 | | Gross Block | - | - | - | | Equity capital | - | 0.00 | - | | EPS (Rs.) | - | 0.00 | - | | DPS (Rs.) | - | - | - | | BV (Rs.) | - | - | - | | P/E range (x) | - | NA | - | | Debt / Equity (x) | - | - | - | | Operating margin (% of OI) | -7.1 | 4.7 | 9.0 | | Net margin (% of OI) | -6.4 | 5.4 | 1.5 |
|
|
Detailed Financials
|
|
|
